.jpg)
Novartis, a prominent name in the global pharmaceutical industry, has recently shared an update about their ongoing global phase III trial, STAND, assessing crizanlizumab. The trial is primarily aimed at examining the efficacy of crizanlizumab in managing vaso-occlusive crises, a common issue in patients with sickle cell disease.
Overview of the STAND trial
The STAND trial (NCT03814746) is a global phase III clinical study initiated by Novartis. The trial is designed to evaluate the effectiveness of two different dosages of crizanlizumab, 5mg/kg and 7.5mg/kg, compared to a placebo in reducing the annualized rates of vaso-occlusive crises leading to healthcare visits within the first year post randomization.
Preliminary Results
The preliminary results of the STAND trial show no significant difference between either dosage of crizanlizumab and the placebo in reducing the number of vaso-occlusive crises.
These results are inconsistent with previous trial results from the SUSTAIN study (NCT01895361), which demonstrated the superiority of crizanlizumab 5.0mg/kg over a placebo.
Safety Profile of Crizanlizumab
Despite the preliminary results, it's essential to note that no new safety concerns have arisen with crizanlizumab. The overall safety profile of crizanlizumab remains consistent with the known profile of the commercially available 5.0mg/kg dose.
Regulatory Review in Progress
Following these findings, regulatory authorities have been informed, and the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has begun a review of crizanlizumab to evaluate the impact of these results on its currently authorized use.
Novartis Response
Novartis is thoroughly reviewing the full data set of the STAND study. The company is working closely with global regulators, including the EMA, which requested data from STAND as part of the conditions for marketing authorization, as well as with the United States Food and Drug Administration (FDA) and trial investigators.
Past Approvals
Crizanlizumab received approval from the FDA in November 2019, with the aim to reduce the frequency of vaso-occlusive crises. In October 2020, the EMA granted conditional Marketing Authorization to prevent recurrent vaso-occlusive crises in patients aged 16 years and above, living with sickle cell disease.
Future Implications
While the assessment of the trial data is ongoing, physicians are advised to consider the individual benefits and risks when making therapeutic decisions regarding the use of crizanlizumab.
Conclusion
The STAND trial results are a vital part of the continuous research and development process in the field of pharmacology. Every clinical trial, whether it meets its primary endpoint or not, contributes to the collective knowledge and advances the cause of patient care. As Novartis continues its thorough review of the STAND trial data, the medical community eagerly awaits further updates.
"The STAND trial results are a vital part of the continuous research and development process in the field of pharmacology" - Anonymous
Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before making any decisions related to treatment.
References
Comments